Clinical trials: Pleural Mesothelioma Malignant
Relapsed Malignant Mesothelioma
A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma
The purpose of this study is to evaluate rising dose levels of VS-5584 administered in combination with a fixed dose of VS-6063 in subjects with relapsed malignant mesothelioma to determine a recommended Phase 2 dose (RP2D) for…
- Trial name
- NCT02372227
- Testing
- VS-5584 and VS-6063
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 21 people
- Sponsor
- Verastem, Inc.
Malignant Pleural Mesothelioma
MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma
Twelve patients with relapsed malignant pleural mesothelioma will be treated with intratumoral injections of MTG201, a replication incompetent adenovirus, modified by the insertion of the reduced expression in immortalized cells…
- Trial name
- NCT04013334
- Testing
- MTG201, Nivolumab Injection [Opdivo]
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Momotaro-Gene Inc.
Advanced Malignant Pleural Mesothelioma
Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced MPM
The main objective of the trial is to document the efficacy of NGR-hTNF administered as maintenance treatment at 0.8 µg/m2 weekly in advanced malignant pleural mesothelioma
- Trial name
- NGR019 (NCT01358084)
- Testing
- NGR-hTNF, Best Supportive Care
- Where
- 15 sites in Germany, Italy and 1 more
- Volunteers
- 137 people
- Sponsor
- AGC Biologics S.p.A.
Solid Tumor, Adult, Colorectal Cancer
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for…
- Conditions
- Solid Tumor, Adult, Colorectal Cancer, Non Small Cell Lung Cancer, Pancreatic Cancer
- Trial name
- BASECAMP-1 (NCT04981119)
- Testing
- Apheresis, Next Generation Sequencing (NGS), Long Range NGS HLA typing
- Where
- 16 sites in United States
- Volunteers
- 500 people
- Sponsor
- A2 Biotherapeutics Inc.
To Determine Safety, Tolerability and Efficacy of ONCOS-102 in Combination With Chemotherapy
A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma
The trial is an open-label, parallel group, multicentre trial that will recruit a total of 30 patients with malignant pleural mesothelioma.
- Trial name
- NCT02879669
- Testing
- ONCOS-102, Pemetrexed/cisplatin (carboplatin), Cyclophosphamide
- Where
- 7 sites in France, Spain
- Volunteers
- 31 people
- Sponsor
- Targovax Oy
Malignant Mesothelioma
Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ecteinascidin 743 in treating patients who have…
- Trial name
- NCT00027508
- Testing
- trabectedin
- Where
- 4 sites in United States
- Sponsor
- PharmaMar
Cancer, Solid Tumor
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
A Phase 1B/2A study will be conducted to establish safety and dose level of AMXT 1501 dicaprate in combination with IV DFMO, in cancer patients.
- Conditions
- Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer
- Trial name
- NCT05500508
- Testing
- AMXT1501, DFMO
- Where
- 7 sites in United States, Australia
- Volunteers
- 15 people
- Sponsor
- Aminex Therapeutics, Inc.
Malignant Pleural Mesotheliomas
Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma
This example study evaluates locoregional allogeneic dual-target mesothelin/FAP CAR-NK cells in adults with unresectable, recurrent, or refractory pleural or peritoneal mesothelioma.
- Trial name
- DUAL-MESO-NK (NCT07510815)
- Testing
- EB-MF-CAR-NK-01, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Beijing Biotech
Malignant Pleural Mesothelioma
Clinical Study of YS110 in Patients With Malignant Pleural Mesothelioma
The purpose of this study is to examine tolerability, safety, and pharmacokinetics of YS110 intravenous administration in patients with malignant pleural mesothelioma and to preliminarily examine the anti-tumor effect of YS110.
- Trial name
- NCT03177668
- Testing
- YS110
- Where
- Japan
- Volunteers
- 40 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Mesothelioma, Malignant
Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM)
This study was originally designed as a multicenter, double-blind, randomized, parallel-group study, using a placebo control or amatuximab 5 milligrams per kilogram (mg/kg), administered weekly, designed to evaluate the safety…
- Trial name
- ARTEMIS (NCT02357147)
- Testing
- Amatuximab, Pemetrexed, Cisplatin
- Where
- 49 sites in United States, Australia and 4 more
- Volunteers
- 124 people
- Sponsor
- Morphotek
Pleural Effusion, Malignant, Ascites, Malignant
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations…
- Conditions
- Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular
- Trial name
- TraveraRTGx (NCT05461430)
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Travera Inc
Ovarian Cancer, Epithelial, Gastric Cancer
A Study of NX-1607 in Adults With Advanced Malignancies
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.
- Conditions
- Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT05107674
- Testing
- NX-1607, Paclitaxel
- Where
- 17 sites in United States, United Kingdom
- Volunteers
- 345 people
- Sponsor
- Nurix Therapeutics, Inc.
Advanced Solid Tumor, Mesothelioma, Malignant
SW-682 in Advanced Solid Tumors
This is a first-in-human (FIH), Phase 1a/1b open-label, multicenter, dose escalation and dose expansion study of SW-682 in adult participants with metastatic or unresectable advanced solid tumors with or without Hippo pathway…
- Trial name
- NCT06251310
- Testing
- SW-682, Combination Therapy
- Where
- 8 sites in United States
- Volunteers
- 186 people
- Sponsor
- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Mesothelioma, Mesothelioma, Malignant
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
Gavocabtagene autoleucel (gavo-cel; TC-210) is a novel cell therapy that consists of autologous genetically engineered T cells expressing a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit…
- Conditions
- Mesothelioma, Mesothelioma, Malignant, Mesothelioma; Pleura, Mesotheliomas Pleural
- Trial name
- NCT03907852
- Testing
- gavo-cel, fludarabine, cyclophosphamide
- Where
- 11 sites in United States, Canada
- Volunteers
- 57 people
- Sponsor
- TCR2 Therapeutics
Malignant Pleural Mesothelioma
Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy
Study of galinpepimut-S, a Wilms Tumor-1 (WT1) vaccine, to see if it delays or prevents the mesothelioma from growing back after surgery. WT1 is a protein in cancer cells that regulates gene expression and causes cell growth.
- Trial name
- NCT01265433
- Testing
- Galinpepimut-S + Montanide + GM-CSF, Montanide + GM-CSF
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Sellas Life Sciences Group
Cervical Cancer, Colorectal Cancer
89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors
A prospective, open-label, phase 2 study to explore CAIX expression through 89Zirconium-labelled girentuximab deferoxamine (89Zr-girentuximab) PET/CT imaging in patients with solid tumors.
- Conditions
- Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- STARBURST (NCT05563272)
- Testing
- 89Zr-girentuximab for PET/CT imaging of CAIX positive tumors
- Where
- 10 sites in United States
- Volunteers
- 11 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Ltd
Mesothelioma
Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment
Malignant mesothelioma is a rare neoplasm that arises most commonly from the mesothelial surfaces of the pleural cavity, occasionally from the peritoneal surface, and rarely from the tunica vaginalis or pericardium.
- Trial name
- NCT01627795
- Testing
- Oshadi D and Oshadi R
- Where
- Israel
- Volunteers
- 17 people
- Sponsor
- Oshadi Drug Administration
Mesothelioma
An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma
This study is a multicentre, open label, non-comparative, two stage phase II trial to assess the activity of ZD1839 (IRESSA) in patients with malignant mesothelioma.
- Trial name
- NCT00787410
- Testing
- ZD1839
- Volunteers
- 23 people
- Sponsor
- AstraZeneca
Advanced Solid Cancer, Non Small Cell Lung Cancer
APG-2449 in Patients With Advanced Solid Tumors
APG-2449 is a novel, orally active, multi-targeted tyrosine kinase inhibitor, which inhibits FAK, ALK, and ROS1 with nanomolar potencies.
- Conditions
- Advanced Solid Cancer, Non Small Cell Lung Cancer, Esophageal Cancer, Ovarian Cancer
- Trial name
- NCT03917043
- Testing
- APG-2449
- Where
- 9 sites in China
- Volunteers
- 165 people
- Sponsor
- Ascentage Pharma Group Inc.
Mesothelioma
Nintedanib (BIBF 1120) in Mesothelioma
This is a phase II/III confirmatory study designed to evaluate the safety and efficacy of nintedanib (BIBF 1120) in combination + (pemetrexed / cisplatin) followed by nintedanib (BIBF 1120) versus placebo + pemetrexed / cisplatin…
- Trial name
- NCT01907100
- Testing
- Nintedanib, Pemetrexed, Cisplatin
- Where
- 123 sites in United States, Argentina and 25 more
- Volunteers
- 545 people
- Sponsor
- Boehringer Ingelheim